By Fineline Cube 
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced Q2 2026 financial results featuring global total revenue of USD 1.7 billion, representing a 30% year-over-year increase. The company also reported GAAP net profit of USD 237 million, up USD 143 million from the same period last year, primarily driven by revenue growth and improved operating leverage.
Financial Highlights | Q2 2026
| Metric | Q2 2026 Result | YoY Change |
|---|---|---|
| Total Revenue | USD 1.7 billion | +30% |
| GAAP Net Profit | USD 237 million | +152% |
| Brukinsa Revenue | USD 1.2 billion | +31% |
| US Brukinsa Sales | USD 893 million | +31% |
| Tislelizumab Sales | USD 229 million | +18% |
| Amgen-Licensed Products | USD 157 million | +25% |
Product Portfolio Performance
- Brukinsa (zanubrutinib): The company’s flagship BTK inhibitor generated USD 1.2 billion in Q2 2026 revenue, up 31% year-over-year. In the critical US market, Brukinsa recorded sales of USD 893 million, also demonstrating a 31% year-over-year increase.
- Tislelizumab: The PD-1 inhibitor achieved global sales of USD 229 million in Q2 2026, marking an 18% year-over-year increase.
- Amgen-Licensed Products: Contributed USD 157 million in global sales during the quarter, up 25% year-over-year, showcasing successful commercial integration.
Updated Full-Year 2026 Guidance
| Metric | Previous Guidance | Updated Guidance |
|---|---|---|
| Total Revenue | Not specified | USD 6.6–6.8 billion |
| GAAP Operating Profit | Not specified | USD 1.0–1.1 billion |
| Non-GAAP Operating Profit | Not specified | USD 1.7–1.8 billion |
The raised guidance reflects strong first-half performance and positive momentum across BeOne’s oncology portfolio, particularly driven by Brukinsa’s continued market penetration and physician adoption globally.
Market Impact & Strategic Outlook
- Oncology Leadership: BeOne continues to strengthen its position as a global oncology leader, with Brukinsa demonstrating consistent double-digit growth across major markets.
- Commercial Execution: The company’s enhanced operating leverage indicates successful scaling of commercial operations and cost management despite global economic headwinds.
- Pipeline Value: Strong cash generation from marketed products provides flexibility to invest in late-stage pipeline assets while maintaining robust shareholder returns.
- Global Expansion: With established presence across US, China, and Europe, BeOne is well-positioned to capture additional market share in emerging oncology markets.
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, product sales, and business outlook. Actual results may differ materially due to risks including competitive pressures, regulatory developments, market adoption rates, and macroeconomic conditions.-Fineline Info & Tech